Patient characteristics and treatment
| Patient (previous identifier) . | Age/sex . | Diagnosis . | Sites of metastases . | TCR . | Culture conditions* . | No. of IL-2 doses . | No. of cells received, ×109 . | % mTCRb+/CD3+ at 1 mo . | Tumor response (duration, mo) . |
|---|---|---|---|---|---|---|---|---|---|
| 1 (7)† | 60/M | Melanoma | In, bo, li, lu, sc | gp100 | S1d7 | 4 | 1.8 | 56 | NR |
| 2 (12)† | 62/M | Melanoma | lu, ln | gp100 | R2d13 | 7 | 47 | 38 | NR |
| 3 | 58/M | Melanoma | iliac ln | gp100 | R2d11 | 8 | 56 | 14 | NR |
| 4 | 56/F | Melanoma | lu | gp100‡ | R2d12 | 4 | 34‡ | 29 | NR |
| 5 (6)§ | 44/M | Melanoma | Right thigh, bilat inguinal and iliac nodes | MAGE A3 | R2d12 | 4 | 53 | 61 | NR |
| 6 (14)† | 51/F | Melanoma | lu, li | gp100 | R2d12 | 6 | 110 | 24 | PR (4) |
| 7 (1)§ | 59/M | Melanoma | lu | MAGE A3 | R2d12 | 6 | 28 | 33 | CR (23+) |
| 8 (11)† | 50/M | Melanoma | retroperit ln, iliac ln; br | gp100 | R2d12 | 8 | 69 | 81 | CR (48+) |
| 9 | 52/M | Melanoma | sc, lu, ln | gp100|| | R2d12 | 6 | 24|| | 44 | PR (3) |
| 10 (4)§ | 21/F | Synovial cell sarcoma | lu | MAGE A3 | R2d12 | 1 | 41 | 86 | PR (5) |
| Patient (previous identifier) . | Age/sex . | Diagnosis . | Sites of metastases . | TCR . | Culture conditions* . | No. of IL-2 doses . | No. of cells received, ×109 . | % mTCRb+/CD3+ at 1 mo . | Tumor response (duration, mo) . |
|---|---|---|---|---|---|---|---|---|---|
| 1 (7)† | 60/M | Melanoma | In, bo, li, lu, sc | gp100 | S1d7 | 4 | 1.8 | 56 | NR |
| 2 (12)† | 62/M | Melanoma | lu, ln | gp100 | R2d13 | 7 | 47 | 38 | NR |
| 3 | 58/M | Melanoma | iliac ln | gp100 | R2d11 | 8 | 56 | 14 | NR |
| 4 | 56/F | Melanoma | lu | gp100‡ | R2d12 | 4 | 34‡ | 29 | NR |
| 5 (6)§ | 44/M | Melanoma | Right thigh, bilat inguinal and iliac nodes | MAGE A3 | R2d12 | 4 | 53 | 61 | NR |
| 6 (14)† | 51/F | Melanoma | lu, li | gp100 | R2d12 | 6 | 110 | 24 | PR (4) |
| 7 (1)§ | 59/M | Melanoma | lu | MAGE A3 | R2d12 | 6 | 28 | 33 | CR (23+) |
| 8 (11)† | 50/M | Melanoma | retroperit ln, iliac ln; br | gp100 | R2d12 | 8 | 69 | 81 | CR (48+) |
| 9 | 52/M | Melanoma | sc, lu, ln | gp100|| | R2d12 | 6 | 24|| | 44 | PR (3) |
| 10 (4)§ | 21/F | Synovial cell sarcoma | lu | MAGE A3 | R2d12 | 1 | 41 | 86 | PR (5) |
bilat, bilateral; bo, bone; br, brain; CR, complete response; li, liver; ln, lymph node; lu, lung; mTCRb+, murine-TCR β-chain positive; NR, no response; PR, partial response; retroperit, retroperitoneal; sc, subcutaneous; TCR, T-cell receptor.
S1d7 indicates initial stimulation with OKT3 and IL-2 during 7 days. R2d11, R2d12, and R2d13 indicate second stimulation with OKT3, IL-2, and feeder cells for 11, 12, and 13 days, respectively, using the Rapid Expansion Protocol.11
Patient identifying number as reported in Johnson et al.4
Also received 0.5e9 MART1 TCR-transduced cells.
Patient identifying number as reported in Morgan et al.8
Also received 23.5e9 MART1 TCR-transduced cells.